CorMedix Inc. (AMEX:CRMD) biopharmaceutical firm, is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.25 per share.
For the full year, analysts predict revenues of $ 0.17 million, while looking forward to loss of $ 0.93 per share.
Previous Quarter Performance
CorMedix Inc. recorded loss for the second quarter of $ 0.14 per share, from the revenue of $ 0.02 million. The quarterly revenues shrunk 84.62 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.14 per share from $ 0.09 million in revenue. The top line results fell short of analysts by $ 0.07 million or 77.78 percent.
Stock Performance
Shares of CorMedix Inc. traded low $ -0.13 or -2.40 percent on Wednesday, reaching $ 5.28 with volume of 239.30 thousand shares. CorMedix Inc. has traded high as $ 5.66 and has cracked $ 5.19 on the downward trend
The closing price of $ 5.28, representing a 150.46 % increase from the 52 week low of $ 2.16 and a 32.12 % decrease over the 52 week high of $ 7.97.
The company has a market capital of $ 164.94 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 29th September 2020, initiated by JMP Securities at Market Outperform rating, with $ 22.00 target price.
Conference Call
CorMedix Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.cormedix.com
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc.
